Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-alpha (IFN-alpha) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC)